{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:48:37Z","timestamp":1789753717217,"version":"4.0.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:p>In this retrospective case series, off-label use of Janus kinase inhibitor rapidly and significantly ameliorated the active cutaneous disease in all five glucocorticoid-resistant patients with cancer-associated dermatomyositis who had anti-transcription intermediary factor 1-\u03b3 antibodies, showing a promising steroid-sparing effect and a generally well-tolerated safety profile beyond 1-year follow-up.<\/jats:p>","DOI":"10.1093\/bjd\/ljad396","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:48:09Z","timestamp":1697536089000},"page":"285-287","source":"Crossref","is-referenced-by-count":5,"title":["Janus kinase inhibitor for anti-transcription intermediary factor 1-\u03b3 positive cancer-associated dermatomyositis"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-7950","authenticated-orcid":false,"given":"Wanlong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Rheumatology"},{"name":"Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-9327","authenticated-orcid":false,"given":"Kaiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"},{"name":"Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-5768","authenticated-orcid":false,"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"2024012322595451200_ljad396-B1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamadermatol.2021.5841","article-title":"Risk-based screening for cancer in patients with dermatomyositis: toward a more individualized approach","volume":"158","author":"Vaughan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024012322595451200_ljad396-B2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024012322595451200_ljad396-B3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024012322595451200_ljad396-B4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2024012322595451200_ljad396-B5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index (CASDI): characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024012322595451200_ljad396-B6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024012322595451200_ljad396-B7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024012322595451200_ljad396-B8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad396\/54022805\/ljad396.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/285\/56345203\/ljad396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/285\/56345203\/ljad396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T23:09:14Z","timestamp":1706051354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/2\/285\/7321086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad396","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,18]]}}}